Xenon Pharmaceuticals Inc (STU:XP0)
€ 38.4 -0.2 (-0.52%) Market Cap: 2.90 Bil Enterprise Value: 2.27 Bil PE Ratio: 0 PB Ratio: 3.56 GF Score: 47/100

Xenon Pharmaceuticals Inc Corporate Update Transcript

Nov 27, 2023 / 01:30PM GMT
Release Date Price: €25.8 (-0.77%)
Operator

Good day and thank you for standing by. Welcome to the Xenon Pharmaceuticals corporate update conference call. (Operator Instructions)

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sherry Aulin, Chief Financial Officer. Please go ahead.

Sherry Aulin
Xenon Pharmaceuticals Inc - Chief Financial Officer

Good morning, everyone. My name is Sherry Aulin, Xenon's Chief Financial Officer, and I will be moderating the call this morning. Thank you for joining us to discuss our top-line results from the Phase 2 proof-of-concept X-NOVA clinical trial of XEN1101 for the treatment of major depressive disorder, or MDD.

Joining me on today's call are Ian Mortimer, Xenon's President and Chief Executive Officer; and Dr. Chris Kenney, Xenon's Chief Medical Officer. Dr. Chris Von Seggern, Xenon's Chief Commercial Officer, will join us for the Q&A session following our prepared remarks.

For those of you on the webinar, there are slides accompanying today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot